The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer

Small cell lung cancer (SCLC) is a deadly neuroendocrine tumor with limited therapeutic options. Recent data suggest that histone deacetylases (HDACs) and the phosphatidylinositol 3-kinase (PI3K) pathway play ...

Source: Journal of Experimental and Clinical Cancer Research - October 17, 2020 Category: Cancer & Oncology Authors: Liying Ma, Xing Bian and Wenchu Lin Tags: Research Source Type: research